| Document |
Document Title |
|
WO/2020/193387A1 |
Compounds of the formula (I) wherein the substituents are as defined in claim 1, useful as a pesticides, especially as fungicides.
|
|
WO/2020/192348A1 |
Disclosed are phenyl allylidene cyclohexenone derivatives with the structure shown in general formula I. In combination with structural characteristics and structure-function relationship of piplartine, amino bonds are replaced with doub...
|
|
WO/2020/185420A1 |
Provided herein are integrated methods and systems for the production of acrylamide and acrylonitrile compounds and other compounds from at least beta-lactones and/or beta-hydroxy amides.
|
|
WO/2020/184330A1 |
A catalyst for acrylonitrile synthesis, which contains a composite body of a metal oxide and a silica that supports the metal oxide, and which is configured such that the ratio of the specific surface area B of the catalyst for acrylonit...
|
|
WO/2020/179671A1 |
This invention provides: a curable resin composition including a specific polymer precursor, a nonionic compound B, and at least one compound selected from the group consisting of a polymerizable compound and a photosensitive compound, w...
|
|
WO/2020/181165A1 |
Provided herein are compounds of formula (I), compositions comprising the compounds and method of treating various diseases with the compounds and compositions.
|
|
WO/2020/177140A1 |
An acrylonitrile catalyst, a preparation method therefor, and application thereof. The acrylonitrile catalyst contains a metal oxide represented by the following general formula: BiaFebNicMgdCeeAfBgChMo12Ox, wherein A is one or more elem...
|
|
WO/2020/173016A1 |
The present invention relates to a resorcinol dianisole derivative, wherein the chemical structure of this compound is as represented by the following formula (I). The compound of the present invention can inhibit the binding of programm...
|
|
WO/2020/175392A1 |
A compound which has a molecular weight of 3,000 or less, while having a partial structure that is represented by formula (X). (In formula (X), ring W1 represents a ring structure that does not have aromaticity, while having at least one...
|
|
WO/2020/175393A1 |
A compound represented by general formula (I). [In formula (I), R3, R4, and R5 each independently represent an electron-attracting group. R1, R2, R6, and R7 each independently represent a hydrogen atom, a heterocyclic group, a halogen at...
|
|
WO/2020/172562A1 |
The present disclosure relates to a process for stabilizing an antimony ammoxidation catalyst in an ammoxidation process. The process may comprise providing an antimony ammoxidation catalyst to a reactor; reacting propylene with ammonia ...
|
|
WO/2020/169047A1 |
Disclosed in the present invention is a 1,1-dicyanohydrazone compound having a novel structure, the structure being as shown in general formula I. See the description for the definitions of each substituent in the formula. The compound o...
|
|
WO/2020/163653A1 |
Improved processes and intermediates for preparing ruxolitinib and deuterated analogs of ruxolitinib are disclosed.
|
|
WO/2020/156297A1 |
Disclosed is a malononitrile compound having a novel structure. The structure is shown in general formula I. See the description for the definition of each substituents in the formula. The compound of general formula I has excellent bact...
|
|
WO/2020/156298A1 |
Disclosed by the present invention is an application of a malononitrile compound as represented by general formula I as a bactericide. See the description for the definition of each substituent in the formula. The compound represented by...
|
|
WO/2020/153414A1 |
The purpose of the present invention is to provide a heterocyclic compound that can have an antagonist activity against an NMDA receptor including an NR2B subunit and is thus expected to be useful as a prophylactic or therapeutic agent f...
|
|
WO/2020/150969A1 |
The present invention provides a diallyl phtalate monomer synthesis method, and belongs to the novel technical field of preparation of high molecular weight monomer by polymerization. An acrylate monomer having a phthalonitrile structure...
|
|
WO/2020/148617A1 |
The present invention disclosed 3-substituted phenylamidine compounds of general formula (I), wherein R1, R2, R3, R4, R4a, R4b, A and E have the same meanings as defined in description. The present invention further discloses methods for...
|
|
WO/2020/148760A1 |
The invention generally concerns a novel class of CB 1 receptor binding molecules and uses thereof.
|
|
WO/2020/143762A1 |
Provided are pamoate salts of ketamine having a stoichiometry of 2: 1 of ketamine to pamoate, including R, S-ketamine pamoate, S-ketamine pamoate, or R-ketamine pamoate, and crystalline or amorphous forms of the pamoate salts, and having...
|
|
WO/2020/127208A2 |
The present disclosure concerns the large-scale manufacture of pharmaceutical compounds, and novel intermediates for use in the manufacture. International Patent Application WO2011154737 discloses morpholine pyrimidines useful for treati...
|
|
WO/2020/119507A1 |
The present application relates to a method for citalopram intermediate 5-citalopram diol. The method comprises: first mixing two Grignard reagents required for a reaction; then mixing the mixed Grignard reagents with a raw material 5-cy...
|
|
WO/2020/104484A1 |
The present invention relates to the synthesis of N-trifluoromethylcarbonyl compounds starting from isothiocyanates, which can be converted into N-trifluoromethylcarbamoyl fluorides or similar compounds, which later on can be derivatized...
|
|
WO/2020/102289A1 |
A process for producing a high-purity acetonitrile product from a low-purity acetonitrile feedstock streams. In particular, the present disclosure relates to a process for producing a sales-grade, high purity acetonitrile by (a) distilli...
|
|
WO/2020/102716A1 |
Disclosed herein a process preparation of 2,6-dichlorobenzonitrile. A process of making high yield, high purity 2,6-dichlorobenzonitrile including the selective de-nitrochlorination of 2-chloro-6-nitrobenzonitrile by treatment of the 2-c...
|
|
WO/2020/094928A1 |
The present disclosure relates to a process for the preparation of 4,5-dihydroxy-2-(4-methylbenzyl)isophthalonitrile, to use of a compound which is 2-methoxy-5-(4-methylbenzyl)phenol, (3-hydroxy-4-methoxyphenyl)(p-tolyl)methanone, 2-meth...
|
|
WO/2020/087233A1 |
Disclosed is an application of an ionic iron (III) complex as a catalyst in preparation of a benzylamine compound, that is, an ionic iron (III) complex having a molecular formula of [(RNCHCHNR)CH][FeBr4] (R is tert-butyl) and containing ...
|
|
WO/2020/085335A1 |
This production method for a 2-cyanoacrylate compound includes: a depolymerization step for depolymerizing a 2-cyanoacrylate polycondensate that is a condensate of a cyanoacetic acid ester compound and a formaldehyde compound in the pres...
|
|
WO/2020/069619A1 |
Method of improving the performance and safety of a Li-ion battery. The method comprises using a nitrile-based small organic compound of general formula I, V or IX outlined below in association with the electrolyte of the battery.
|
|
WO/2020/064818A1 |
Industrially viable and advantageous processes for the preparation of Ozanimod are described. The invention also discloses the intermediates obtained in the process.
|
|
WO/2020/058058A1 |
The present invention pertains to pro-fragrances and relates to a pro-fragrance compound of the formula (I). Furthermore, the invention relates to compositions, a laundry product, a home care product, and an insect repellant, comprising ...
|
|
WO/2020/061367A1 |
The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions fu...
|
|
WO/2020/049436A1 |
The present invention relates to a method for the preparation of fluoroalkyl nitrile of Formula I and their use to prepare related fluoroalkyl tetrazole of Formula II in the presence of the dehydrating agent, wherein, x1 and x2 have the ...
|
|
WO/2020/049957A1 |
The present invention provides a compound having an excellent rate of HTP change by exposure to light. In addition, the present invention provides a composition, a cured product, an optically anisotropic body, and a reflective film, whic...
|
|
WO/2020/043997A1 |
The present invention relates to 1,4-dimethyltetrazenes of formula (la), (Ib) and (le): R1-CH2-N(CH3)-N=N-N(CH3)-CH2-R2 (la) R3-CH2-CH2-N(CH3)-N=N-N(CH3)-CH2-CH2-R4 (Ib) R5-CHOH-CH2-N(CH3)-N=N-N(CH3)-CH2-CHOH-R5 (lc), in which RI, R2, R3...
|
|
WO/2020/037372A1 |
A method of detecting the presence of an NBOMe in a sample which comprises of contacting the sample with an activated p-quinone such as 2,3,5,6-tetrachloro-1,4-benzoquinone (TCBQ) and an aldehyde, for example acetaldehyde, and optionally...
|
|
WO/2020/039998A1 |
The purpose of the present invention is to provide a method of producing an ammoxidation catalyst that exhibits high acrylonitrile yield, and a method of producing acrylonitrile. This method of producing an ammoxidation catalyst involves...
|
|
WO/2020/039985A1 |
The purpose of the present invention is to provide a method for producing an ammoxidation catalyst which enables synthesizing acrylonitrile with high yield. This method for producing an ammoxidation catalyst involves a preparation step f...
|
|
WO/2020/037209A1 |
A series of benzosuberene analogues demonstrate effective inhibition of tubulin polymerization, cytotoxicity against human cancer cell lines, and vascular dismption in tumors.
|
|
WO/2020/030093A1 |
A pharmaceutical composition containing an M-diamide compound and an application thereof. The pharmaceutical composition comprises an active ingredient A and an active ingredient B, the active ingredient A is an M-diamide compound having...
|
|
WO/2020/030092A1 |
A pharmaceutical composition containing an m-diamide compound and an application thereof. The pharmaceutical composition comprises an active component A and an active component B, wherein the active component A is the m-diamide compound ...
|
|
WO/2020/033567A1 |
In one aspect, the disclosure relates to methods for preparation of intermediates useful for the preparation of aryl-cycloheptene scaffolds. In a further aspect, the disclosed methods pertain to the preparation of compounds comprising an...
|
|
WO/2020/030096A1 |
A drug composition containing an M-diamide compound and application of the drug composition. The drug composition comprises an effective constituent A and an effective constituent B; the effective constituent A is the M-diamide compound ...
|
|
WO/2020/030094A1 |
Provided are a pharmaceutical composition comprising a meta-diamide compound and the use thereof. The pharmaceutical composition includes an active ingredient A and an active ingredient B, wherein the active ingredient A is a meta-diamid...
|
|
WO/2020/031179A1 |
The present invention provides simple synthetic routes for the preparation of cannabinoid compounds such as CBD, CBDV, THC, THCV, CBN, HU-308, CBG, CBC, and derivatives thereof, which are stereoselective and provide the desired cannabino...
|
|
WO/2020/025749A1 |
The present disclosure encompasses crystalline forms of N1-(1-cyanocycloproply)-N2- ((1S)-1-{4'-[(1R-2,2-difluoro-1-hydroxyethyl]biphenyl-4-yl}-
2,2,2-trifluoroethyl)-4-fluoro-L- leucinamide and processes for the preparation thereof.
|
|
WO/2020/025499A1 |
The present invention relates to the field of chemical components for electrolyte compositions which are useful in electrochemical cells, such as lithium-ion batteries. More specifically, the invention provides components and their combi...
|
|
WO/2020/025748A1 |
A method of preparing a compound of Formula (I) comprising reacting the compound of Formula (A) with a base and a compound of Formula (B) to yield a compound of Formula (C).
|
|
WO/2020/020969A1 |
The present disclosure relates to 4,5-dihydroxy-2-(4-methylbenzyl)isophthalonitrile solvates, including hydrates, and crystalline forms thereof and to methods for preparing said solvates and crystalline forms thereof.
|
|
WO/2020/017246A1 |
Provided are a photoreaction apparatus and method by which throughput is improved while suppressing an increase in the size of the apparatus. The photoreaction apparatus includes a reaction unit (47), a light source unit (13), and a cool...
|
